FDA raises concerns of 'early deaths' in Abecma and Carvykti multiple myeloma trials
An FDA advisory committee will vote Friday on whether two CAR-T therapies, Carvykti and Abecma, have a favorable benefit-risk ratio in earlier lines of multiple …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
